Rohit Kapoor Takes Money Off The Table, Sells $4.14M In ExlService Holdings Stock
Making a noteworthy insider sell on November 5, Rohit Kapoor, Chairman & CEO at ExlService Holdings EXLS, is reported in the latest SEC filing.
What Happened: Kapoor’s decision to sell 100,000 shares of ExlService Holdings was revealed in a Form 4 filing with the U.S. Securities and Exchange Commission on Tuesday. The total value of the sale is $4,145,000.
ExlService Holdings‘s shares are actively trading at $45.89, experiencing a up of 6.52% during Wednesday’s morning session.
Unveiling the Story Behind ExlService Holdings
ExlService Holdings Inc. is a business process management company that provides digital operations and analytical services to clients driving enterprise-scale business transformation initiatives that leverage company’s deep expertise in analytics, AI, ML and cloud. The company offers business process outsourcing and automation services, and data-driven insights to customers across multiple industries. The company operates through four segments based on the products and services offered and markets served: Insurance, Healthcare, Emerging, Analytics. The vast majority of the company’s revenue is earned in the United States, and more than half of its revenue comes from Analytics segment.
A Deep Dive into ExlService Holdings’s Financials
Positive Revenue Trend: Examining ExlService Holdings’s financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 14.87% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Industrials sector.
Exploring Profitability:
-
Gross Margin: The company issues a cost efficiency warning with a low gross margin of 37.76%, indicating potential difficulties in maintaining profitability compared to its peers.
-
Earnings per Share (EPS): ExlService Holdings’s EPS reflects a decline, falling below the industry average with a current EPS of 0.33.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.47.
Valuation Overview:
-
Price to Earnings (P/E) Ratio: A higher-than-average P/E ratio of 37.79 suggests caution, as the stock may be overvalued in the eyes of investors.
-
Price to Sales (P/S) Ratio: A higher-than-average P/S ratio of 4.02 suggests overvaluation in the eyes of investors, considering sales performance.
-
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation & Amortization): At 20.87, the company’s EV/EBITDA ratio outperforms industry norms, reflecting positive market perception. This positioning indicates optimistic expectations for the company’s future performance.
Market Capitalization Highlights: Above the industry average, the company’s market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.
The Importance of Insider Transactions
While insider transactions should not be the sole basis for making investment decisions, they can play a significant role in an investor’s decision-making process.
In legal terms, an “insider” refers to any officer, director, or beneficial owner of more than ten percent of a company’s equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down.
Exploring Key Transaction Codes
Taking a closer look at transactions, investors often prioritize those unfolding in the open market, meticulously cataloged in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C denotes the conversion of an option, and transaction code A signifies a grant, award, or other acquisition of securities from the company.
Check Out The Full List Of ExlService Holdings’s Insider Trades.
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don’t miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. Click here for access.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.
Market News and Data brought to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Insider Decision: Bruce C Cozadd Offloads $110K Worth Of Jazz Pharmaceuticals Stock
Bruce C Cozadd, Chairman & CEO at Jazz Pharmaceuticals JAZZ, disclosed an insider sell on November 5, according to a recent SEC filing.
What Happened: Cozadd’s decision to sell 1,000 shares of Jazz Pharmaceuticals was revealed in a Form 4 filing with the U.S. Securities and Exchange Commission on Tuesday. The total value of the sale is $110,840.
In the Wednesday’s morning session, Jazz Pharmaceuticals‘s shares are currently trading at $108.82, experiencing a down of 0.54%.
Get to Know Jazz Pharmaceuticals Better
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Jazz Pharmaceuticals’s Economic Impact: An Analysis
Positive Revenue Trend: Examining Jazz Pharmaceuticals’s financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 6.95% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Exploring Profitability:
-
Gross Margin: The company sets a benchmark with a high gross margin of 89.27%, reflecting superior cost management and profitability compared to its peers.
-
Earnings per Share (EPS): Jazz Pharmaceuticals’s EPS is below the industry average, signaling challenges in bottom-line performance with a current EPS of 2.68.
Debt Management: With a below-average debt-to-equity ratio of 1.54, Jazz Pharmaceuticals adopts a prudent financial strategy, indicating a balanced approach to debt management.
Insights into Valuation Metrics:
-
Price to Earnings (P/E) Ratio: The P/E ratio of 18.89 is lower than the industry average, implying a discounted valuation for Jazz Pharmaceuticals’s stock.
-
Price to Sales (P/S) Ratio: With a P/S ratio of 2.0 below industry standards, the stock shows potential undervaluation, making it an appealing investment option for those focusing on sales performance.
-
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation & Amortization): At 8.8, Jazz Pharmaceuticals’s EV/EBITDA ratio reflects a below-par valuation compared to industry averages signalling undervaluation
Market Capitalization Analysis: Below industry benchmarks, the company’s market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.
Uncovering the Importance of Insider Activity
Emphasizing the importance of a comprehensive approach, considering insider transactions is valuable, but it’s crucial to evaluate them in conjunction with other investment factors.
From a legal standpoint, the term “insider” pertains to any officer, director, or beneficial owner holding more than ten percent of a company’s equity securities as outlined in Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and significant hedge funds. These insiders are mandated to inform the public of their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
A company insider’s new purchase is a indicator of their positive anticipation for a rise in the stock.
While insider sells may not necessarily reflect a bearish view and can be motivated by various factors.
Understanding Crucial Transaction Codes
In the domain of transactions, investors frequently turn their focus to those taking place in the open market, as meticulously outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
Check Out The Full List Of Jazz Pharmaceuticals’s Insider Trades.
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don’t miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. Click here for access.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.
Market News and Data brought to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Herc Hldgs Insider Trades Send A Signal
Mark Humphrey, SVP & Chief Financial Officer at Herc Hldgs HRI, executed a substantial insider sell on November 5, according to an SEC filing.
What Happened: Humphrey’s decision to sell 2,625 shares of Herc Hldgs was revealed in a Form 4 filing with the U.S. Securities and Exchange Commission on Tuesday. The total value of the sale is $551,488.
The latest market snapshot at Wednesday morning reveals Herc Hldgs shares up by 6.02%, trading at $228.0.
Get to Know Herc Hldgs Better
Herc Holdings is an equipment rental company that was spun out of Hertz Global in 2016. It is currently the third-largest equipment rental company (4% market share) in North America, after United Rentals and Sunbelt Rentals, with a fleet size of $6.4 billion. It serves commercial and residential construction customers, the environmental sector, industrial entities, and entertainment production companies. During much of its 50-year-plus history, the company has rented equipment such as aerial lifts to its customers for intermittent use. More recently, it has broadened its catalog to include a host of specialty items. Separately, Herc Holdings’ strategy now incorporates long-term rentals to industrial customers where Herc maintains its own staff at the customer site.
Breaking Down Herc Hldgs’s Financial Performance
Revenue Growth: Herc Hldgs’s remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 6.28%. This signifies a substantial increase in the company’s top-line earnings. When compared to others in the Industrials sector, the company excelled with a growth rate higher than the average among peers.
Key Profitability Indicators:
-
Gross Margin: Achieving a high gross margin of 39.9%, the company performs well in terms of cost management and profitability within its sector.
-
Earnings per Share (EPS): Herc Hldgs’s EPS is significantly higher than the industry average. The company demonstrates a robust bottom-line performance with a current EPS of 4.3.
Debt Management: Herc Hldgs’s debt-to-equity ratio stands notably higher than the industry average, reaching 3.49. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
Assessing Valuation Metrics:
-
Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 17.6 is lower than the industry average, indicating potential undervaluation for the stock.
-
Price to Sales (P/S) Ratio: The P/S ratio of 1.78 is lower than the industry average, implying a discounted valuation for Herc Hldgs’s stock in relation to sales performance.
-
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation & Amortization): With a lower-than-industry-average EV/EBITDA ratio of 7.44, Herc Hldgs presents a potential value opportunity, as investors are paying less for each unit of EBITDA.
Market Capitalization: Indicating a reduced size compared to industry averages, the company’s market capitalization poses unique challenges.
Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.
Understanding the Significance of Insider Transactions
In the complex landscape of investment decisions, investors should approach insider transactions as part of a comprehensive analysis, considering various elements.
Within the legal framework, an “insider” is defined as any officer, director, or beneficial owner holding more than ten percent of a company’s equity securities as per Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
The initiation of a new purchase by a company insider serves as a strong indication that they expect the stock to rise.
However, insider sells may not always signal a bearish view and can be influenced by various factors.
Essential Transaction Codes Unveiled
In the domain of transactions, investors frequently turn their focus to those taking place in the open market, as meticulously outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
Check Out The Full List Of Herc Hldgs’s Insider Trades.
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don’t miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. Click here for access.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.
Market News and Data brought to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Lumos Pharma Inc. – LUMO
NEW YORK, Nov. 06, 2024 (GLOBE NEWSWIRE) — Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Lumos Pharma Inc. (NYSE: LUMO), relating to its proposed merger with Double Point Ventures LLC. Under the terms of the agreement, Double Point Ventures will acquire Lumos Pharma’s outstanding shares of common stock for $4.25 per share in cash, plus one non-transferable unsecured Contingent Value Right per share payable on achievement of certain milestones.
Click here for more information https://monteverdelaw.com/case/lumos-pharma-inc-lumo/. It is free and there is no cost or obligation to you.
NOT ALL LAW FIRMS ARE THE SAME. Before you hire a law firm, you should talk to a lawyer and ask:
- Do you file class actions and go to Court?
- When was the last time you recovered money for shareholders?
- What cases did you recover money in and how much?
About Monteverde & Associates PC
Our firm litigates and has recovered money for shareholders…and we do it from our offices in the Empire State Building. We are a national class action securities firm with a successful track record in trial and appellate courts, including the U.S. Supreme Court.
No company, director or officer is above the law. If you own common stock in the above listed company and have concerns or wish to obtain additional information free of charge, please visit our website or contact Juan Monteverde, Esq. either via e-mail at jmonteverde@monteverdelaw.com or by telephone at (212) 971-1341.
Contact:
Juan Monteverde, Esq.
MONTEVERDE & ASSOCIATES PC
The Empire State Building
350 Fifth Ave. Suite 4740
New York, NY 10118
United States of America
jmonteverde@monteverdelaw.com
Tel: (212) 971-1341
Attorney Advertising. (C) 2024 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com). Prior results do not guarantee a similar outcome with respect to any future matter.
Market News and Data brought to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
PLAZACORP WILLOWGROVE RESIDENTIAL REAL ESTATE DEVELOPMENT TRUST FILES PRELIMINARY PROSPECTUS FOR INITIAL PUBLIC OFFERING OF UNITS
TORONTO, Nov. 5, 2024 /CNW/ – Plazacorp Willowgrove Residential Real Estate Development Trust (the “REDT“) announced today that it has filed, and obtained a receipt for, a preliminary prospectus with the securities regulatory authorities in each of the provinces of Canada, other than Québec, for a proposed initial public offering of its trust units (the “Offering“).
The preliminary prospectus qualifies the distribution of a minimum of C$60 million and a maximum of C$75 million of Class A Units and/or Class F Units of the REDT at a price of C$10.00 per Class A Unit and Class F Unit.
The REDT is a newly-created, unincorporated investment trust, currently owned by Plazacorp Investments Limited (“Plazacorp“), and was established for the primary purpose of indirectly owning a majority equity interest in a project (the “Project“) to develop two residential subdivisions comprising 676 residences (467 townhomes and 209 single detached homes), and 297 serviced lots on 213 acres of land in Markham and Stouffville, Ontario.
The REDT will aim to develop the Project and, commencing on the sale of homes in the Project, declare and pay to unitholders of the REDT cash distributions out of the available cash flow.
The current owners of the Project will retain a minority ownership interest in the Project following the closing of the Offering and the acquisition of an interest in the Project by the REDT, as further specified in the preliminary prospectus. None of the current owners will receive any of the net proceeds of the Offering, which will be used to pay the costs and expenses of the Offering and to fund the development of the Project, as further specified in the preliminary prospectus.
Significant development approval and pre-development progress has been made to date, including zoning and subdivision approvals, finalization of a Master Environmental Servicing Plan in conjunction with the area municipalities, Conservation Authority and Regional government, and assembling a multidisciplinary team of local counsel, architects, planners and engineers to comprehensively design the sites. Total forecasted costs for the Project are approximately C$804.2 million.
The REDT will be managed by Plazacorp Willowgrove REDT Management Inc., an affiliate of Plazacorp, and administered by a board of trustees, a majority of whom are considered independent by the REDT. The Project will be developed by Plazacorp Upper Markham Management Limited Partnership, a limited partnership which will be controlled by Plazacorp that will earn certain fees in connection with the development of the Project and the sale of lots in the Project.
CIBC World Markets Inc. (the “Agent“) is the sole agent for the Offering.
This press release does not constitute an offer to sell or the solicitation of an offer to buy securities of the REDT in the United States, nor shall there be any sale of the securities of the REDT in any jurisdiction in which such offer, solicitation or sale would be unlawful. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the “1933 Act“), and may not be offered or sold within the United States unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to exemptions from the registration requirements of the U.S. Securities Act and applicable state securities laws.
A preliminary prospectus containing important information relating to these securities has been filed with securities regulatory authorities in each of the provinces of Canada, other than Québec. The preliminary prospectus is still subject to completion or amendment. A copy of the preliminary prospectus may be obtained from the Agent and is available on SEDAR+ at www.sedarplus.com. There will not be any sale or any acceptance of an offer to buy the securities until a receipt for the final prospectus has been issued.
Plazacorp Willowgrove Residential Real Estate Development Trust
Plazacorp Willowgrove Residential Real Estate Development Trust was established for the primary purpose of indirectly owning an interest in a project to develop two residential subdivisions comprising 676 residences (467 townhomes and 209 single detached homes), and 297 serviced lots on 213 acres of land in Markham and Stouffville, Ontario.
Forward-Looking Statements
This news release contains statements that include forward-looking information within the meaning of Canadian securities laws. These forward-looking statements reflect the current expectations of the REDT regarding future events, including statements concerning the use of proceeds of the Offering, expectations with respect to the development of the Project, the timing of construction and completion, expected construction plans, the expected number and breakdown of units constructed and the sale of units. In some cases, forward-looking statements can be identified by terms such as “may”, “might”, “will”, “could”, “should”, “would”, “occur”, “expect”, “plan”, “anticipate”, “believe”, “intend”, “seek”, “aim”, “estimate”, “target”, “project”, “predict”, “forecast”, “potential”, “continue”, “likely”, “schedule”, or the negative thereof or other similar expressions concerning matters that are not historical facts.
Material factors and assumptions used by management of the REDT to develop the forward-looking information include, but are not limited to, the REDT’s current expectations about: construction and development risk; obtaining necessary development permits for the Project; the realization of property value appreciation and timing thereof; the inventory of residential properties; competition from developers of residential properties; the Markham and Stouffville, Ontario real estate markets; government legal and regulatory changes; property encumbrances relating to the Project; closing and other transaction costs in connection with the acquisition and disposition of the Project; the availability of financing and current interest rates; demographic trends; fluctuations in interest rates; litigation risks; the relative illiquidity of real property investments; the Canadian economic environment; the geographic concentration of the REDT’s business; natural disasters and severe weather; demand levels for residential properties in Markham and Stouffville, Ontario and local economic conditions; negative geopolitical events; public health crises; the capital structure of the REDT; distributions; capital depletion; potential conflicts of interest; reliance on the good faith and ability of the Project’s project manager to manage the Project; the limited operating history of the REDT; the limited experience of management of the REDT with respect to managing a reporting issuer; the limited liquidity of the Class A Units and Class F Units; and tax laws. While management of the REDT considers these assumptions to be reasonable based on currently available information, they may prove to be incorrect.
Although management believes the expectations reflected in such forward-looking statements are reasonable and represent the REDT’s internal projections, expectations and beliefs at this time, such statements involve known and unknown risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities may not be achieved. A variety of factors, many of which are beyond the REDT’s control, could cause actual results in future periods to differ materially from current expectations of estimated or anticipated events or results expressed or implied by such forward-looking statements. Such factors include the risks identified in the preliminary prospectus, including under the heading “Risk Factors” therein. Readers are cautioned against placing undue reliance on forward-looking statements. Except as required by applicable Canadian securities laws, the REDT undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events.
SOURCE Plazacorp Willowgrove Residential Real Estate Development Trust
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/November2024/05/c7392.html
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Body Contouring Treatments Market to Hit USD 2.58 Billion by 2029 with 10.0% CAGR | MarketsandMarkets™
Delray Beach, FL, Nov. 06, 2024 (GLOBE NEWSWIRE) — The global body contouring treatments market growth forecasted to transform from USD 1.46 billion in 2024 to USD 2.58 billion by 2029, driven by a CAGR of 10.0%. from 2024 to 2029. Over the years, this body contouring treatments has evolved significantly, focusing on improved patient safety and decreased follow ups. These innovations combined with reduced downtime and rising awareness for body contouring procedures, has driven the market growth. As healthcare advances, body contouring devices contribute to enhanced outcomes with the improved safety profiles for the patients as well as operators. Use body contouring devices for wide range of applications continues to drive innovation and breakthroughs in different domains, benefiting humanity in multiple ways.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=59695724
Browse in-depth TOC on “Body Contouring Treatments Market“
237 – Tables
58 – Figures
261 – Pages
The body contouring treatments market is segmented based on technology into invasive and non-invasive technologies—the non-invasive segment is expected to hold major share of the market in 2023. The reduced risk of complications and rising awareness of the advantages of non-invasive procedures is driving the growth of this segment.
By application, the body contouring treatments market is segmented into non-surgical fat reduction, cellulite treatment, liposuction, abdominoplasty, and other applications. In 2023, the non-surgical fat reduction segment held a significant share of the market 2023. Minimal downtime and less risk compared to traditional surgery are driving the growth of this segment. Minimal downtime feature increases the patient convenience that leads to decreased recovery period further supporting the market growth.
By patient type, the body contouring treatments market is segmented into male patients and female patients. In 2023, the female segment held the largest share of the market 2023. Increasing desire to achieve defined body and social media influence are driving the growth of this segment. Rising number of medical spas and increasing awareness related to the benefits of these procedures further support the segment growth.
Regarding end users, the body contouring treatments market is fragmented into hospitals, aesthetic clinics and medical spas & beauty centers. The major share of the market was contributed by hospitals segment in 2023. Increasing funding opportunities and rising focus on healthcare research and by private and public entities are fuelling the market’s growth. Furthermore, increasing number of aesthetic clinics and rise funding opportunities in past few years support the growth of the end user segment.
The body contouring treatments market is segmented by region into Europe, North America, Asia Pacific, Latin America, and Middle East & Africa. In 2023, North America region accounted for the major market share, followed by Europe and Asia Pacific. The significant share of North America in this market is attributed to the strong existence of key players, rising number of obesity cases, increasing medical tourism. Factors such as increasing healthcare expenditure and growing popularity for various aesthetics treatment support the market growth in the region.
Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=59695724
The body contouring treatments market is competitive. As of 2023, the key players operating in the global body contouring treatments market are AbbVie Inc. (US), InMode Ltd. (Israel), Bausch Health Companies Inc. (Canada), Cynosure Lutronic (US), Sisram Medical Ltd (Israel). The top players in this market have adopted key strategies such as partnerships, acquisitions, and expansions in the last four years. In 2023, AbbVie Inc. (US), InMode Ltd. (Israel), Bausch Health Companies Inc. (Canada) held a major share of the body contouring treatments market.
AbbVie Inc. (US):
Abbvie Inc. is among the leading companies in the global body contouring treatments market. AbbVie has a direct distribution network that spans across multiple continents. The company operates in North America, Europe, the Asia Pacific, Latin America, and the Middle East through its subsidiaries. The company offers body contouring devices through other aesthetics segment. The company focuses on enhancing its product portfolio and continuous innovation and developing new products to sustain its leading position in the market.
Bausch Health Companies Inc. (Canada):
Bausch Health Companies Inc. (Bausch) is a multinational pharmaceutical and medical device company that develops, manufactures, and markets a wide range of healthcare products. The company offers medical aesthetics products including body contouring devices through its Solta Medical segment. The company has a geographical presence in more than 90 countries and regions, including the US, Canada, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. Bausch has currently operated approximately 35 manufacturing sites worldwide, of which 24 are Bausch + Lomb facilities. Bausch Health Companies Inc. has a strong brand value among body contouring device end users, strong R&D capabilities, and a robust product portfolio.
Inmode Ltd. (Israel):
Inmode Ltd. is another major player operating in the body contouring treatments market. It offers innovative aesthetic solutions and provides body contouring products under the capital equipment revenues segment. The company is committed to research & development to create and launch new tools that enhance patient outcomes. In June 2022, InMode Ltd. has collaborated with Clinisept+ to provide best skin recovery with minimal patient downtime. The company has global business offices in the US and Canada, Latin America, Europe, the Middle East, Africa, the Asia Pacific, Australia & New Zealand, France, and Italy.
For more information, Inquire Now!
Related Reports:
Cardiac Monitoring Devices Market
Patient Monitoring Devices Market
Respiratory Care Devices Market
Get access to the latest updates on Body Contouring Treatments Companies and Body Contouring Treatments Market Size
About MarketsandMarkets™ MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients. Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes. The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry. To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook. Contact: Mr. Rohan Salgarkar MarketsandMarkets Inc. 1615 South Congress Ave. Suite 103, Delray Beach, FL 33445 USA : 1-888-600-6441 UK +44-800-368-9399 Email: sales@marketsandmarkets.com Visit Our Website: https://www.marketsandmarkets.com/
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
American Homes 4 Rent Insider Trades Send A Signal
JACK CORRIGAN, Board Member at American Homes 4 Rent AMH, reported an insider sell on November 5, according to a new SEC filing.
What Happened: CORRIGAN’s decision to sell 100,000 shares of American Homes 4 Rent was revealed in a Form 4 filing with the U.S. Securities and Exchange Commission on Tuesday. The total value of the sale is $3,519,450.
At Wednesday morning, American Homes 4 Rent shares are up by 2.71%, trading at $36.36.
Get to Know American Homes 4 Rent Better
American Homes 4 Rent is a real estate investment trust primarily focused on acquiring, operating, and leasing single-family homes as rental properties throughout the United States. The company’s real estate portfolio is largely comprised of single-family properties in urban markets in the Southern and Midwestern regions of the U.S. American Homes 4 Rent’s land holdings also represent a sizable percentage of its total assets in terms of value. The company derives the vast majority of its income in the form of rental revenue from single-family properties through short-term or annual leases. The firm’s largest geographical markets include Dallas, Texas; Indianapolis, Indiana; Atlanta, Georgia; and Charlotte, North Carolina in terms of the number of properties in each.
American Homes 4 Rent’s Economic Impact: An Analysis
Revenue Growth: American Homes 4 Rent’s remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 5.54%. This signifies a substantial increase in the company’s top-line earnings. When compared to others in the Real Estate sector, the company excelled with a growth rate higher than the average among peers.
Navigating Financial Profits:
-
Gross Margin: With a high gross margin of 54.16%, the company demonstrates effective cost control and strong profitability relative to its peers.
-
Earnings per Share (EPS): American Homes 4 Rent’s EPS reflects a decline, falling below the industry average with a current EPS of 0.2.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.65.
Evaluating Valuation:
-
Price to Earnings (P/E) Ratio: With a lower-than-average P/E ratio of 36.88, the stock indicates an attractive valuation, potentially presenting a buying opportunity.
-
Price to Sales (P/S) Ratio: With a higher-than-average P/S ratio of 7.63, American Homes 4 Rent’s stock is perceived as being overvalued in the market, particularly in relation to sales performance.
-
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation & Amortization): At 16.78, American Homes 4 Rent’s EV/EBITDA ratio reflects a below-par valuation compared to industry averages signalling undervaluation
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.
The Relevance of Insider Transactions
Considering insider transactions is valuable, but it’s crucial to evaluate them in conjunction with other investment factors.
Considering the legal perspective, an “insider” is defined as any officer, director, or beneficial owner holding more than ten percent of a company’s equity securities, according to Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Pointing towards optimism, a company insider’s new purchase signals their positive anticipation for the stock to rise.
Nevertheless, insider sells may not necessarily indicate a bearish view and can be influenced by various factors.
A Deep Dive into Insider Transaction Codes
Examining transactions, investors often concentrate on those unfolding in the open market, meticulously detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C indicates the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
Check Out The Full List Of American Homes 4 Rent’s Insider Trades.
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don’t miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. Click here for access.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.
Market News and Data brought to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Syringes Market Share, Key Drivers, Restraints, and Emerging Trends 2024 to 2033 – Exactitude Consultancy
Luton, Bedfordshire, United Kingdom, Nov. 06, 2024 (GLOBE NEWSWIRE) — The emerging markets in the Asia-Pacific region present significant growth opportunities for companies involved in the development and production of syringes. Key factors contributing to this market expansion include advancements in technology, heightened interest from global players, rapid urbanization, favourable regulatory environments facilitating the approval of new injectables, and a swift increase in the aging population.
To estimate the sizes and growth rates of the syringe market and its various subsegments, a blend of bottom-up and top-down analytical methods was employed. All percentage shares, splits, and breakdowns were determined using secondary sources and subsequently validated through primary sources. Comprehensive parameters influencing the market have been thoroughly analyzed, and both quantitative and qualitative data have been compiled. Primary interviews with industry leaders helped in assessing the market share of each product globally. The report provides insights into growth rates and market drivers for all subsegments, mapping out market sizes and growth trajectories while identifying segments likely to experience rapid growth in each geographic area.
The rise in chronic diseases and the increasing number of vaccinations that heavily rely on syringes, particularly single-use and disposable types, are key contributors to the growth of the global market. The International Diabetes Federation (IDF) Diabetes Atlas predicts that the diabetic population will rise by 46% to reach 643 million by 2030, with a significant increase expected in middle-income countries compared to developed nations. The shift toward disposable medical supplies aimed at preventing infections during hospital procedures is another crucial factor propelling market growth.
The trend of self-administered medications underscores the importance of safety when using syringes. The introduction of disposable syringes has mitigated the risk of cross-contamination by allowing users to dispose of needles immediately after use. Mölnlycke Health Care AB highlights that around 70 million surgical procedures are conducted annually in Europe, contributing to a projected rise in syringe sales in the coming years and further driving market expansion.
Access PDF Sample Report (Including Graphs, Charts & Figures) @
https://exactitudeconsultancy.com/reports/6828/prefilled-syringes-market/#request-a-sample
Increased Use of Self-Administered Medications Driving Syringe Sales in the United States
The syringes market in the United States is anticipated to generate an absolute growth opportunity of $5.7 billion by 2033, with projections indicating a growth rate of 2.5 times during the forecast period from 2023 to 2033.
As of 2022, the U.S. held a substantial market share of 25.7%, solidifying its position as a key player in the syringes industry. The increase in syringe sales across the nation can be linked to several factors, including the rising incidence of chronic and infectious diseases, the growing adoption of self-administered medications, the availability of standardized syringes, and the presence of major syringe manufacturers. Additionally, the expansion of sectors such as the prefilled syringes industry, home healthcare market, and insulin syringe market significantly contributes to this growth.
The escalating prevalence of chronic and infectious conditions, particularly diabetes and influenza, is a primary driver behind the growth of the syringe market. According to the CDC’s National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP), 6 in 10 adults in the United States live with a chronic disease. This results in substantial annual expenditures on insulin injections, flu vaccines, and other related medical treatments, further fueling the demand for syringes.
Precision at Its Best: Trends in the Syringes Industry in Germany
In 2022, Germany held a 8.2% share of the syringes market, underscoring its significant role in the industry. A prominent trend in this region is the strong emphasis on quality and precision. German manufacturers are committed to utilizing advanced manufacturing technologies and implementing stringent quality control protocols to ensure the production of top-tier syringes. Moreover, there is an increasing focus on sustainable manufacturing practices, which includes the use of eco-friendly materials and energy-efficient production processes.
Synergy of Technology and Care: Trends in the Syringes Industry in Japan
Japan represented 3.8% of the market share in 2022, affirming its importance in the global syringes landscape. The region is recognized for its technological advancements across various sectors, including healthcare. Japanese manufacturers are leading the way in creating innovative syringe designs that enhance functionality, precision, and user-friendliness. Continuous advancements in materials, such as self-lubricating plastics and biocompatible coatings, have further propelled the growth of the syringes industry in Japan.
Empowering Healthcare Delivery: Trends in the Syringes Industry in Australia
Australia accounted for 1.5% of the syringes market in 2022, highlighting its contribution to the industry. A significant trend in this region is the increasing adoption of prefilled syringes. These prefilled syringes offer numerous benefits, including a reduction in medication errors, enhanced dosage accuracy, and greater convenience for both healthcare professionals and patients. The rising demand for self-administered medications, along with the growth in chronic disease cases, is driving the acceptance and use of prefilled syringes in Australia.
Redefining Accessibility: Trends in the Syringes Industry in China
In 2022, China achieved a CAGR of 6.7%, establishing itself as a significant player in the global syringes market. The nation has experienced a notable transition towards the production of low-cost syringes that cater to both domestic and international markets. Chinese manufacturers capitalize on economies of scale and advanced production capabilities, enabling them to offer competitive pricing while maintaining high quality standards. Furthermore, there is an increasing integration of automation into the syringe manufacturing processes, resulting in enhanced production efficiency and substantial cost savings.
Innovation Meets Quality: Trends in the Syringes Industry in the United Kingdom
The United Kingdom accounted for 3.7% of the market share in 2022, affirming its significance in the global syringes industry. The region is characterized by stringent regulatory standards and a strong commitment to product quality. Manufacturers in the UK are dedicated to developing cutting-edge syringe technologies that prioritize patient safety and enhance the overall healthcare experience. The rising demand for self-administration syringes, coupled with the increasing prevalence of chronic diseases, is propelling market growth in the region. Additionally, the UK’s robust healthcare infrastructure and strategic collaborations with pharmaceutical companies provide a competitive advantage in the syringes sector.
Report Link Click Here: https://exactitudeconsultancy.com/reports/6828/prefilled-syringes-market/
Rising Vaccine Consumption Boosts Demand for Disposable Syringes in India
India is poised to capture over 35% of the South Asia syringes market share during the forecast period, driven by evolving attitudes towards vaccination, a rapidly growing population, heightened health awareness, and an expanding disposable syringes industry. The syringes market in India is projected to experience a CAGR of 10.5% throughout this period, according to FMI.
As one of the fastest-growing economies globally, India boasts a substantial population of over 1.38 billion. This demographic advantage positions the country as a promising market for disposable syringes. Several factors contribute to this growth, including increasing government initiatives aimed at vaccinating every newborn, a robust presence of syringe manufacturers, and a rising awareness of the latest trends in the syringes market. These elements collectively foster an environment conducive to the expansion of the syringes industry in India.
Key Players :
- Becton
- Dickinson and Company
- Gerresheimer AG
- Braun Medical Inc.
- Schott AG
- DWK Life Sciences
- CODAN Medizinische Geräte GmbH & Co KG
- Cardinal Health Inc.
- CHEMI S.P.A.
- Terumo Corporation
- NIPRO Corporation
- Hindustan Syringes
- Medical Devices Ltd.
Recent Developments by Key Players in Syringes Market:
- Medtronic (August 2023): Medtronic announced the launch of its new auto-injector platform designed for chronic disease management. The platform incorporates user-friendly features and advanced dosing technology to improve patient adherence and comfort during self-administration of medications.
- Fresenius Kabi (June 2023): Fresenius Kabi unveiled its new line of prefilled syringes that utilize cutting-edge sterilization methods to ensure maximum safety and efficacy. The syringes are designed for a wide range of medications, including vaccines and biologics.
- Schott AG (September 2023): Schott AG has introduced a new line of glass syringes with enhanced barrier properties. These syringes are designed to protect sensitive biologics from environmental factors, improving drug stability and shelf life.
- Gerresheimer AG (July 2023): Gerresheimer AG launched a range of disposable syringes featuring an innovative safety mechanism that reduces the risk of accidental needlestick injuries. This new design aims to enhance safety for healthcare workers during medication administration.
- B. Braun (October 2023): B. Braun announced an investment in expanding its syringe production facility in Mexico to meet growing global demand. The expansion includes the implementation of advanced automation technologies to increase production efficiency and ensure high-quality manufacturing standards.
Syringes Market Segments:
This research report categorizes the market size of syringes into the following segments:
By Usability
- Sterilizable/Reusable Syringes
- Hypodermic Syringes
- Oral Syringes
- Disposable Syringes
- Conventional Syringes
- Safety Syringes
- Retractable Safety Syringes
- Non-Retractable Safety Syringes
- Prefilled Syringes
By Material
- Glass Syringes
- Plastic Syringes
By Type
- General Syringes
- Specialized Syringes
- Insulin Syringes
- Tuberculin Syringes
- Allergy Syringes
- Other Syringes
By Region
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa
Get a Sample PDF Brochure:
https://exactitudeconsultancy.com/reports/6828/prefilled-syringes-market/#request-a-sample
Related Reports:
Powder Coatings Market
https://exactitudeconsultancy.com/reports/2775/powder-coatings-market/
The global Powder Coatings Market is expected to grow at more than 4.2% CAGR from 2020 to 2029. It is expected to reach above USD 20.79 billion by 2029 from USD 12.56 billion in 2020.
Fire-resistant Coatings Market
https://exactitudeconsultancy.com/reports/2777/fire-resistant-coatings-market/
The global fire-resistant coating market is expected to grow at 3% CAGR from 2022 to 2029. It is expected to reach above USD 1065.40 million by 2029 from USD 975 million in 2020.
Super Absorbent Polymers Market
https://exactitudeconsultancy.com/reports/1542/super-absorbent-polymers-market/
The Global Super Absorbent Polymers market is expected to grow at 7.10% CAGR from 2023 to 2028. It is expected to reach above USD 12.5 billion by 2028 from USD 7.5 billion in 2022.
Tank Insulation Market
https://exactitudeconsultancy.com/reports/861/tank-insulation-market/
The Global Tank Insulation Market is expected to grow at more than 5.6% CAGR from 2023 to 2025. It is expected to reach above USD 7 billion by 2025 from a little above USD 5 billion in 2022.
Silicon Carbide (SiC) Market
https://exactitudeconsultancy.com/reports/2786/silicon-carbide-sic-market/
The global silicon carbide (SiC) market is expected to grow at 7% CAGR from 2022 to 2029. It is expected to reach above USD 787.44 million by 2029 from USD 428.31 million in 2020.
Antimicrobial Coatings Market
https://exactitudeconsultancy.com/reports/2582/antimicrobial-coatings-market/
The global antimicrobial coatings market size was USD 3.7 Billion in 2020 and is projected to reach USD 9.54 Billion by 2029, exhibiting a CAGR of 11% during the forecast period.
3D Printing Material Market
https://exactitudeconsultancy.com/reports/1804/3d-printing-material-market/
The Global 3D printing material Market is expected to grow at more than 23% CAGR from 2019 to 2028. It is expected to reach above USD 6 billion by 2028 from a little above USD 2 billion in 2019.
Adhesives & Sealants Market
https://exactitudeconsultancy.com/reports/1762/adhesives-sealants-market/
The adhesives & sealants market is expected to grow at 5% CAGR from 2022 to 2029. It is expected to reach above USD 80.6 billion by 2029 from USD 51.9 billion in 2020.
Thermoplastic Elastomers Market
https://exactitudeconsultancy.com/reports/1584/thermoplastic-elastomers-market/
The Global Thermoplastic Elastomers Market is expected to grow at 6.90% CAGR from 2023 to 2028. It is expected to reach above USD 25.5 billion by 2028 from USD 16.00 billion in 2022.
Polyimide Films Market
https://exactitudeconsultancy.com/reports/1544/polyimide-films-market/
Polyimide Films Market was valued at USD 1.4 Billion in 2022 and is projected to reach USD 4 Billion by 2028, growing at a CAGR of 11.7% from 2023 to 2028.
Insulating Paints and Coatings Market
https://exactitudeconsultancy.com/reports/884/insulating-paints-and-coatings-market/
The Global Insulating Paints & Coatings Market is expected to grow at more than 5.8% CAGR from 2023 to 2028. It is expected to reach above USD 13.7 billion by 2028 from a little above USD 8 billion in 2022.
EMEA Refrigerants Market
https://exactitudeconsultancy.com/reports/1101/emea-refrigerants-market/
The EMEA Refrigerants Market is expected to grow at more than 6% CAGR from 2023 to 2026. It is expected to reach above USD 6 billion by 2026 from USD 4.1 billion in 2022.
Irfan Tamboli (Head of Sales) Phone: + 1704 266 3234 Email: sales@exactitudeconsultancy.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.